<DOC>
	<DOCNO>NCT00365898</DOCNO>
	<brief_summary>The objective study assess efficacy safety 8 mg Hydromorphone Hydrochloride Extended-Release .</brief_summary>
	<brief_title>Efficacy Safety Hydromorphone Hydrochloride Extended-Release Compared Placebo Subjects With Persistent Pain</brief_title>
	<detailed_description>The primary efficacy objective study compare time emergence inadequate analgesia 8 mg Hydromorphone Hydrochloride Extended-Release take every 24 hour versus placebo treatment patient persistent pain require opioid medication control pain .</detailed_description>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>persistent , moderatetosevere noncancer relate pain require continuous analgesia week month , long , currently take 20 40 mg oxycodone opioid equivalent per day control persistent pain willing accept possibility receive placebo DoubleBlind Phase Patients already receive opioid medication average total daily dose great 40 mg oxycodone opioid equivalent last week prior study entry . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Chronic non-malignant pain , opioid</keyword>
</DOC>